ShockCO-OP - Shock and acute Conditions OutcOmes Platform Consortium

 

Scientific coordinators

Alastair Proudfoot (Barts Heart Centre, Barts Health NHS Trust, London, UK)
Sabri Soussi (Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada)

Steering committee

Susanna Price (Royal Brompton Hospital, Imperial College London, London, UK)
Patrick Lawler (McGill University Health Centre, McGill University, Montreal, QC, Canada)
Alexandre Mebazaa (Lariboisière - Saint-Louis Hospitals, Assistance Publique-Hôpitaux de Paris Nord, University of Paris Cité, France)

About the ShockCO-OP consortium

The Shock and Acute Conditions Outcomes Platform (ShockCO-OP) is a global consortium focused on advancing translational research with a focus on precision medicine approaches in the management of cardiogenic shock (CS).  

It is an open, inclusive platform, welcoming participation from any interested investigators to build a ‘Network of Networks’ in translational CS research. ShockCO-OP aims to address key challenges in the field of CS by fostering longitudinal, paired clinical and biological data sharing. The goal of the ShockCO-OP is to accelerate biological/molecular sub-phenotyping in CS to enhance precision medicine approaches and overcome sample size limitations that have hindered progress in the field.

Further, ShockCO-OP endeavors to serve as a forum for thought leaders and research networks to interface and collaborate with standardization of protocols including prospective biospecimen collection, biomarker measurement, and the use of machine learning approaches to maximize efficiency and quality.

The core aims of ShockCO-OP are:

  • To foster and champion a global collaboration amongst established CS research networks.

  • To support the development of local capacity for investigator-led research through mentorship, specifically in underrepresented regions.

  • To advance the science and methodology of translational research in CS with a focus on biological/molecular subphenotyping and precision medicine approaches.

  • To explore secondary hypotheses and disentangle the heterogeneity observed within CS populations and their clinical outcomes

  • To explore biological/molecular subphenotypes in cardiogenic shock that may be targeted in mechanistic trials and support prognostic/predictive trial enrichment.

References

Mebazaa A, Soussi S. Precision Medicine in Cardiogenic Shock: We Are Almost There! JACC Heart Fail. 2023;11(10):1316-1319. 

Soussi S, Tarvasmäki T, Kimmoun A, Ahmadiankalati M, Azibani F, Dos Santos CC, Duarte K, Gayat E, Jentzer JC, Harjola VP, Hibbert B, Jung C, Johan L, Levy B, Lu Z, Lawler PR, Marshall JC, Pöss J, Sadoune M, Nguyen A, Raynor A, Peoc'h K, Thiele H, Mathew R, Mebazaa A. Identifying biomarker-driven subphenotypes of cardiogenic shock: analysis of prospective cohorts and randomized controlled trials. EClinicalMedicine. 2024;79:103013. 

Soussi S, Price S, Proudfoot A, Mebazaa A, Lawler PR. Why Molecular Subphenotyping Is Needed in Cardiogenic Shock, and How to Accomplish This? Am J Respir Crit Care Med. 2025 Jan 13 [Epub ahead of print]. 

Contact

If you are interested in more information or would like to join the ShockCO-OP consortium, please contact ShockCO-OP@uhn.ca